Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01157845 · ClinicalTrials.gov registry record · Phase 3

Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

A Phase 3 study of Cirrhosis, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 3
Development phase
165
Enrollment target
4
Study locations

NCT01157845: Completed Phase 3 study of Cirrhosis, sponsored by Virginia Commonwealth University.

NCT01157845 is a Phase 3 study of Cirrhosis that has completed, run by Virginia Commonwealth University. The registered enrollment target is 165 participants, below the 90,406-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01157845, a Phase 3 study of Cirrhosis, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 3
Development phase
165 participants
Enrollment target
4
Study locations

Study Summary

The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.

Primary Outcome

Patient dies of liver-related causes within 1 year of study entry

Conditions Studied

Interventions

  • DEVICE BreathID (Methacetin breath test)

Study Locations (4)

Michigan

  • Henry Ford Health System - Detroit

South Carolina

  • Medical University of South Carolina - Charleston

Virginia

  • Virginia Commonwealth University Medical Center - Richmond

Israel

  • Hadassah Medical Center - Jerusalem

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2010-03
Est. Completion 2012-07
Phase Phase 3
Virginia Commonwealth University

558 total trials

What the finished NCT01157845 record still lists

NCT01157845 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 90,406-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which BreathID (Methacetin breath test) is the first listed.

NCT01157845 reports a single indexed study location in Michigan, South Carolina, Virginia.

Frequently Asked Questions

What is clinical trial NCT01157845 about?

NCT01157845 is a clinical study titled "Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis". The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver functio...

What is the current status of trial NCT01157845?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2010-03. Estimated completion is 2012-07.

What conditions does trial NCT01157845 study?

This clinical trial studies the following conditions: Cirrhosis.

What interventions are being tested in trial NCT01157845?

The interventions under investigation include: BreathID (Methacetin breath test) (DEVICE).

Who is sponsoring clinical trial NCT01157845?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01157845 being conducted?

This trial has 4 study locations across Michigan, South Carolina, Virginia, Israel. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01157845's enrollment target sits among peer trials

165 15th of 53 higher than 39 of 53 other Cirrhosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01157845, the US trial registry maintained by the National Library of Medicine. NCT01157845 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.